Fortnightly Review: A rational approach to the management of hepatitis C infection

BMJ

Volumn 312, Issue 7027, 1996, Pages 357-364

  Dusheiko, G M ^a   Khakoo, S ^a   Soni, P ^a   Grellier, L ^a  

^a ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS C ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; RIBAVIRIN; VIRUS RNA;

ACUTE PSYCHOSIS; ALCOHOL CONSUMPTION; ANXIETY; APPETITE DISORDER; AUTOIMMUNITY; BACTERIAL INFECTION; CHRONIC HEPATITIS; DEPRESSION; DISEASE COURSE; ENZYME ACTIVITY; FEVER; GENOTYPE; HAIR LOSS; HEADACHE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOASSAY; IMMUNOBLOTTING; IRRITABILITY; LEUKOPENIA; LIVER CIRRHOSIS; MALAISE; PATIENT COUNSELING; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEIZURE; SIDE EFFECT; THROMBOCYTOPENIA; VIRUS REPLICATION; VIRUS TRANSMISSION;

ACUTE DISEASE; CHRONIC DISEASE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; RNA, VIRAL;

EID: 0030048114     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.312.7027.357     Document Type: Article

References (44)

1. Dusheiko G, Simmonds P. Sequence variability of hepatitis C virus and its clinical relevance. Journal of Viral Hepatitis 1994; 1: 3–15.
2. Simmonds P, Alberti A, Alter HJ, Bonino F, Bradley DW, Brechot C, et al. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology 1994; 19: 1321–4.
3. Lesniewski R, Okasinski G, Carrick R, Van Sant C, Desai S, Johnson R, et al. Antibody to hepatitis C virus second envelope (HCV-E2) glycoprotein: a new marker of HCV infection closely associated with viremia. J Med Virol 1995; 45: 415–22.
4. Ferrari C, Valli A, Galati L, Penna A, Scaccaglia P, Giuberti T, et al. T-cell response to structural and nonstructural hepatitis C virus antigens in persistent and self-limited hepatitis C virus infections. Hepatology 1994; 19: 286–95.
5. Sawada M, Takada A, Takase S, Takada N. Effects of alcohol on the replication of hepatitis C virus. Alcohol Alcohol 1993; suppl 1B: 85–90.
6. Miyakawa H, Sato C, Izumi N, Tazawa J, Ebata A, Hattori K, et al. Hepatitis C virus infection in alcoholic liver cirrhosis in Japan: its contribution to the development of hepatocellular carcinoma. Alcohol Alcohol 1993; suppl 1A: 85–90.
7. El Gohary A, Hassan A, Nooman Z, Lavanchy D, Mayerat C, El Ayat A, et al. High prevalence of hepatitis C virus among urban and rural population groups in Egypt. Acta Trop (Basel) 1995; 59: 155–61.
8. Dusheiko GM, Smith M, Scheuer PJ. Hepatitis C transmitted by a human bite. Lancet 1990; 336: 503–4.
9. Eyster ME, Alter HJ, Aledort LM, Quan S, Hatzakis A, Goedert JJ. Heterosexual co-transmission of hepatitis C virus (HCV) and human immunodeficiency virus (HIV). Ann Intern Med 1991; 115: 764–8.
10. Zanetti AR, Tanzi E, Paccagnini S, Principi N, Pizzocolo G, Caccamo ML, et al. Mother-to-infant transmission of hepatitis C virus. Lancet 1995; 345: 289–91.
11. Weiner AJ, Thaler MM, Crawford K, et al. HCV-positive, HIV-1-negative mothers transmit HCV. In: Nishioko K, Suzuki H, Mishiro K, Oda T, eds. Viral hepatitis and liver disease. Tokyo: Springer Verlag, 1994; 463–7.
12. Thaler MM, Park C-K, Landers DV, Wara DW, Houghton M, Veereman-Wauters G, et al. Vertical transmission of hepatitis C virus. Lancet 1991; 338: 17–8.
13. Lenzi M, Johnson PJ, McFarlane IG, Ballardini G, Smith HM, McFarlane BM, et al. Antibodies to hepatitis C virus in autoimmune liver disease: evidence for geographical heterogeneity. Lancet 1991; 338: 277–80.
14. Meyer zum Buschenfelde KH, Lohse AW, Gerken G, Treichel U, Lohr H-F, Mohr H, et al. The role of autoimmunity in hepatitis C infection. J Hepatol 1995; 22(suppl 1):93–6.
15. Garcia-Buey L, Garcia-Monzon C, Rodriguez S, Borque MJ, Garcia-Sanchez A, Iglesias R, et al. Latent autoimmune hepatitis triggered during interferon therapy in patients with chronic hepatitis C. Gastroenterology 1995; 108: 1770–7.
16. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HCJ, Perrillo RP, et al. Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. N Engl J Med 1989; 321: 1501–6.
17. Di-Bisceglie AM, Martin P, Kassianides C, Lisker-Melman M, Murray L, Waggoner J, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med 1989; 321: 1506–10.
18. Varagona G, Brown D, Kibbler H, Scheuer P, Ashrafzadeh P, Sherlock S, et al. Response, relapse and retreatment rates and viraemia in chronic hepatitis C treated with a2b interferon. A phase III study. European Journal of Gastroenterology and Hepatology 1992; 4: 707–12.
19. Lok AS-F, Lai C-L, Leung EK-Y. Interferon antibodies may negate the antiviral effects of recombinant a-interferon treatment in patients with chronic hepatitis B virus infection. Hepatology 1990; 12: 1266–70.
20. Mayet WJ, Hess G, Gerken G, Rossol S, Voth R, Manns M, et al. Treatment of chronic type B hepatitis with recombinant alpha-interferon induces autoantibodies not specific for autoimmune chronic hepatitis. Hepatology 1989; 10: 24–28.
21. Renault PF, Hoofnagle JH. Side effects of alpha interferon. Semin Liver Dis 1989; 9: 273–7.
22. Carella C, Amato G, Biondi B, Rotondi M, Morisco F, Tuccillo C, et al. Longitudinal study of antibodies against thyroid in patients undergoing interferon-(alpha) therapy for HCV chronic hepatitis. Horm Res 1995; 44: 110–4.
23. Shindo M, Arai K, Sokawa Y, Okuno T. Hepatic hepatitis C virus RNA as a predictor of a long-term response to interferon-a therapy. Ann Intern Med 1995; 122: 586–91.
24. Orito E, Mizokami M, Suzuki K, Ohba K, Ohno T, Mori M, et al. Loss of serum HCV RNA at week 4 of interferon-a therapy is associated with more favorable long-term response in patients with chronic hepatitis C. J Med Virol 1995; 46: 109–15.
25. Kanai K, Kako M, Aikawa T, Kumada T, Kawasaki T, Hatahara T, et al. HCV RNA monitoring for tailored regimens of interferon therapy in hepatitis C. Biomed Pharmacother 1995; 49: 65–67.
26. Reichard O, Foberg U, Fryden A, Mattsson L, Norkrans G, Sonnerborg A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-a(sub 2b) for 60 weeks. Hepatology 1994; 19: 280–5.
27. Simmonds P, Mellor J, Craxi A, et al. Epidemiological, clinical and therapeutic associations of hepatitis C types in western European patients. J Hepatol (in press).
28. Yamada G, Takahashi M, Tsuji T, Yoshizawa H, Okamoto H. Quantitative HCV RNA and effect of interferon therapy in chronic hepatitis C. Dig Dis Sci 1992; 37: 1926–7.
29. Suzuki T, Tanaka E, Matsumoto A, Urushihara A, Sodeyama T. Usefulness of simple assays for serum concentration of hepatitis C virus RNA and HCV genotype in predicting the response of patients with chronic hepatitis C to interferon a2a therapy. J Med Virol 1995; 46: 162–8.
30. Chemello L, Bonetti P, Cavalletto L, Talato F, Donadon V, Casarin P, et al. Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C. Hepatology 1995; 22: 700–6.
31. Enomoto N, Sakuma K, Asahina Y, et al. Mutations in the non-structural protein 5a gene and response to interferon in patients with chronic hepatitis B 1b infection. N Engl J Med 1996; 334: 77–81. (Abstract.)
32. Poynard T, Bedossa P, Chevallier M, Mathurin P, Lemonnier C, Trepo C, et al. A comparison of three interferon alfa-2b regimens for the long term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995; 332: 1457–62.
33. Nishiguchi S, Kuroki T, Nakatani S, Morimoto H, Takeda T, Nakajima S, et al. Randomised trial of effects of interferon-a on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995; 346: 1051–5.
34. Fernandez H, Banks G, Smith R. Ribavirin: a clinical overview. Eur J Epidemiol 1986; 2: 1–14.
35. Dusheiko G, Main J, Thomas H, Reichard O, Lee C, Dhillon A, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. Journal of Hepatology 1996: in press.
36. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812–7.
37. Attili AF, Rusticali A, Varriale M, Carli L, Repice AM, Callea F. The effect of ursodeoxycholic acid on serum enzymes and liver histology in patients with chronic active hepatitis. A 12-month double-blind, placebo-controlled trial. J Hepatol 1994; 20: 315–20.
38. Takano S, Ito Y, Yokosuka O, Ohto M, Uchiumi K, Hirota K, et al. A multicenter randomized controlled dose study of ursodeoxycholic acid for chronic hepatitis C. Hepatology 1994; 20: 558–64.
39. Beloqui O, Prieto J, Suarez M, Gil B, Qian CH, Garcia N, et al. N-acetyl cysteine enhances the response to interferon-a in chronic hepatitis C: a pilot study. J Interferon Res 1993; 13: 279–82.
40. Van Thiel DH, Friedlander L, Fagiuoli S, Wright HI, Irish W, Gavaler JS. Response to interferon (alpha) therapy is influenced by the iron content of the liver. J Hepatol 1994; 20: 410–5.
41. Girelli CM, Mirata C, Lesinigo E, Casiraghi A. Iron overload and response to a-interferon in chronic hepatitis C. Am J Gastroenterol 1995; 90: 170–1.
42. Clemente MG, Congia M, Lai ME, Lilliu F, Lampis R, Frau F, et al. Effect of iron overload on the response to recombinant interferon-alfa treatment in transfusion-dependent patients with thalassemia major and chronic hepatitis C. J Pediatr 1994; 125: 123–8.
43. Hayashi H, Takikawa T, Nishimura N, Yano M, Isomura T, Sakamoto N. Improvement of serum aminotransferase levels after phlebotomy in patients with chronic active hepatitis C and excess hepatic iron. Am J Gastroenterol 1994; 89: 986–8.
44. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108–13.